Home » Health Policy » Pharmaceutical Policy and Regulation

Category Archives: Pharmaceutical Policy and Regulation

Reductions in Mid-Life Diabetes, Hypertension Increase Future Number of Americans with Dementia

Using large data sets and dynamic modeling, researchers find that improving cardiovascular health at middle and older ages is not enough to slow the growth in the number of older Americans with dementia further underscoring the need for treatment innovations that will delay or prevent dementia.   (more…)

Prescription Drug Coupons: A One-Size-Fits-All Policy Approach Doesn’t Fit The Evidence

Critics of prescription drug copayment coupons contend that they force insurers to cover more expensive brand drugs and cause overall costs to rise. The counterpoint is notes that with rising drug copayments, coupons reduce patients’ out-of-pocket costs and provide access to needed therapies. The truth is more complex.  (more…)

Follow the Money to Understand How Drug Profits Flow

Only by following the money will a clear understanding emerge of the economic forces roiling the industry and driving price increases. (more…)

Treatment-Specific Payment Approaches: The Case Of Macular Degeneration

Treatment for neovascular or wet age-related macular degeneration (nAMD) is an area where a change in Medicare Part B payment specific to this procedure has far more potential for substantial reductions in spending. (more…)

Pharmaceutical Industry Profits And Research And Development

Paul Ginsburg and Richard Frank question the premise that more innovation is always a good thing.  (more…)

How Health Care Providers Can Help End the Overprescription of Opioids

Battling the opioid epidemic requires flexible, carefully designed, and rapidly evaluated policies.  (more…)

Switch and Save on Medicare Part D

Simply switching prescription drug plans could save seniors and the government billions. (more…)

A Billion Here, a Billion There: Selectively Disclosing Actual Generic Drug Prices Would Save Real Money

Opportunities exist to lower spending on generic drugs—and reduce total health care spending.


Reining In Pharmaceutical Costs

The administration and lawmakers should prioritize four actions that could engender more cooperation and improve health over the long-term. (more…)

Follow The Money: The Flow Of Funds In The Pharmaceutical Distribution System

Any government intervention to control drug pricing should be predicated on a clear understanding of the economic forces that drive price increases, and the parties responsible for them. (more…)

Follow CESR on Facebook

Follow Schaeffer on Facebook